News

PLAXGEN GRANTED UNITED STATES PATENT FOR METHOD, COMPOSITION, ISOLATION AND IDENTIFICATION OF A PLAQUE PARTICLE AND RELATED BIOMARKER

Fremont, CA—April 11, 2017, The disclosure relates to an in vitro technology of detecting presence of a plaque particle, isolating the plaque particle followed by its composition analysis in several diseases states or before the disease sets in. A mechanism and a process leading to plaque formation, identifying a component in the mechanism of plaque formation, an identification of a biomarker for diagnosis/early diagnosis of plaque associated disease is described. A method of screening a candidate agent as an anti-plaque agent using flow cytometer, mass spectrometer and specific biomarkers is performed. Provided also are kits for use in practicing embodiment of the methods. A plaqueproteome database is also generated with novel protein sequences for diagnosis and specific antibodies for specific proteins are also disclosed.

PLAXGEN TO PRESENT AT THE THIRD NEUROLOGICAL DISORDERS SUMMIT-2017

Presentation at 13:35pm PST on July 6th, 2017

Fremont, CA—July 6, 2017, Plaxgen Inc, a biodiagnostic company developing proprietary Plaque array tests for diagnosis of atherosclerosis and Alzheimer’s Disease is scheduled to present at the 3rd Neurological disorders summit-2017. Founder & CEO, Dr. Shanmugavel Madasamy will present the data on “In-vitro Imaging Based Screening of Alzheimer’s Disease Serum Samples for Determining Abeta, Tau and Cholesterol Responses” on July 6th, 2017 at 13:35 pm PST at the Crowne Plaza Hotel located at 1177 Airport Blvd. Burlingame, CA 94010. More


PLAXGEN INC RECEIVES 2017 BEST OF FREMONT AWARD

Fremont Award Program Honors the Achievement

FREMONT June 1, 2017 — Plaxgen Inc has been selected for the 2017 Best of Fremont Award in the Medical Services category by the Fremont Award Program.More


PLAXGEN PILOTS TEST FOR PREDICTING STATIN RESPONSE WITH REGIONAL HOSPITAL GROUP

NEW YORK (GenomeWeb) —OCTOBER 27, 2016, – Diagnostics firm Plaxgen has launched its StatRes test for predicting patient response to statins to a limited number of customers..More

PLAXGEN STATIN STUDY PUBLISHED IN CARDIOLOGY JOURNAL

Identifies New Statin Mechanism of Action Regulating Cholesterol Particles Formation

Fremont, CA—OCTOBER 3, 2016,Plaxgen, Inc., developing flow cytometry-based blood diagnostics for plaque-associated diseases, such as atherosclerosis and Alzheimer’s, announced that research exploring the effect of statins on cholesterol particles formation in human serum samples was published in the peer-reviewed publication, “The American Journal of Cardiology.” In the paper, “Non-Enzymatic Mechanism of Statins In Modulating Cholesterol Particles Formation,” researchers examined the effect of multiple commercially-available statins on low-density and high-density cholesterol particles formation in blood serum samples using Plaxgen’s proprietary Plaque Array platform. The Plaque Array technique combines flow cytometry and particle-targeted proteomics to identify the precise makeup of plaque particles derived from serum.More

PLAXGEN INC RECEIVES 2016 BEST OF FREMONT AWARD

Fremont Award Program Honors the Achievement

FREMONT May 18, 2016 — Plaxgen Inc has been selected for the 2016 Best of Fremont Award in the Medical Services category by the Fremont Award Program.More


PLAXGEN INVITED TO PRESENT AT THE NEUROLOGICAL DISORDERS SUMMIT-2015

Presentation at 16:45pm PST on July 7th, 2015

Fremont, CA—July 6, 2015, Plaxgen Inc, a biodiagnostic company developing proprietary Plaque array tests for diagnosis of atherosclerosis and Alzheimer’s Disease has been invited to present at the Neurological disorders summit-2015. Founder & CEO, Dr. Shanmugavel Madasamy will present “Plaque array and particles targeted proteomics based identification of serum biomarkers for Alzheimer’s Disease” on July 7th, 2015 at 16:45 pm PST at the DoubleTree by Hilton Hotel San Francisco Airport located at 835 Airport Blvd, Burlingame, CA 94010. Also, Dr. Madasamy will Chair the second day of the scientific session. More


PLAXGEN GRANTED SECOND UNITED STATES PATENT FOR ASSAY, COMPOSITION AND NON-ENZYMATIC MECHANISM OF STATIN IN MODULATING LIPID METABOLISM

Fremont, CA—June 2, 2015, A novel non-enzymatic assay for lipid modulating drugs is being described for biological samples. For the first time non-enzymatic mechanism of statin drugs in modulating lipid aggregates and forming lipid particles is being shown. A simple flow cytometer based testing for detection of lipid particles, the effect of lipid modulating drug such as statin in vitro and testing for efficacy of the drug for an individual, dosage adjustment and drug discovery mechanism is being described. The lipid modulating drugs either individually or in combination can be discovered, optimized or efficacy tested using this assay. A novel statin response assay using serum samples described can be used for diagnosis, personalized medicine and biomarker identification as well.

STUDY ON PLAXGEN ALZHEIMER’S DISEASE BLOOD DIAGNOSTIC PUBLISHED IN PEER-REVIEWED JOURNAL

Plaque Array Method Shown Effective in Quantifying and Identifying Blood Plaque Components Possibly Implicated in Alzheimer’s

SUNNYVALE, CA—February 20, 2015, Plaxgen, Inc., developing flow cytometry-based blood diagnostics for plaque-associated diseases, such as atherosclerosis and Alzheimer’s, announced that a paper validating its Plaque Array technology for the diagnosis of Alzheimer’s disease, was published in the peer-reviewed journal, Clinica Chimica Acta. In a study called, “Plaque Array Method and Proteomics-based Identification of Biomarkers from Alzheimer’s Disease Serum,” researchers concluded that the Plaque Array methodology developed by Plaxgen works well for detecting abeta and other particle formation in the blood serum of subjects clinically-determined to have Alzheimer’s disease (AD). The Plaque Array technique, which incorporates particle- targeted proteomics to identify the makeup of the plaques, was also effective in identifying the various components of those particles: abeta 42, tau, cholesterol and synuclein. This could be beneficial in the development of therapeutics targeted to these specific AD pathologies. More


PLAQUE ARRAY METHOD LINKS BLOOD PLAQUE COMPONENTS TO ALZHEIMER’S

DDNEWS-SUNNYVALE, Calif.—Plaxgen Inc., a developer of flow cytometry-based blood diagnostics for plaque-associated illnesses such as atherosclerosis and Alzheimer’s disease, announced that a paper validating its Plaque Array technology for the diagnosis of Alzheimer’s disease was published in the peer-reviewed journal Clinica Chimica Acta. In a study titled “Plaque Array Method and Proteomics-based Identification of Biomarkers from Alzheimer’s Disease Serum,” researchers concluded that the Plaque Array methodology developed by Plaxgen works well for detecting amyloid beta (Abeta) and other particle formation in the blood serum of subjects clinically determined to have Alzheimer’s disease (AD). More

Dx FIRM PLAXGEN MOVING PLAQUE-BASED ALZHEIMER’S, ATHEROSCLEROSIS TESTS TOWARD COMMERCIALIZATION

NEW YORK (GenomeWeb) – Having spent the last seven years prepping its technology, proteomic diagnostics firm Plaxgen is now moving tests for Alzheimer’s disease and atherosclerosis towards commercialization.First in line is the company’s Alzheimer’s diagnostic, named Amyload, for which it is currently planning a validation study expected to begin in June 2015 and run through approximately January 2016, Plaxgen Founder and CEO Shanmugavel Madasamy told GenomeWeb.The company plans to offer the test initially out of its Fremont, Calif.-based CLIA facility while simultaneously filing for US Food and Drug Administration 510(k) clearance, he said, noting that it plans to target the test to pharma firms that would use it for selecting patients for clinical trials and measuring response to treatment. More

PLAXGEN GRANTED UNITED STATES PATENT FOR MULTI-SUBUNIT BIOLOGICAL COMPLEXES FOR TREATMENT OF PLAQUE-ASSOCIATED DISEASES

SUNNYVALE, CA—January 18, 2015, Provided herein are methods and compositions for the in vitro formation of multi subunit biological platforms. The biological platforms may be used to screen chemical or biological compounds, in particular compounds that may disrupt or otherwise affect the formation of the multi subunit complexes, or disrupt already-formed in vitro assembled multi subunit complexes. Also provided herein are methods and compositions for the in vivo formation of multi-subunit biological complexes. The methods and compositions described herein may be used to develop animal models, diagnostics, drug discovery targeting a broad spectrum of plaque related diseases or disorders.